Devansh Mishra’s Latest Research Highlights Hypercoagulable State in COPD
Devansh Mishra, Associate at Trainee Research AssoCiation of KGMU (TRACK), shared a post on LinkedIn:
“New Publication Alert!
Thrilled to share our latest research article, “Evaluation of Prothrombotic Biomarkers in Stable and Exacerbation Phases of Chronic
Obstructive Pulmonary Disease: A Cross-Sectional Study,” published in Cureus.
Chronic Obstructive Pulmonary Disease (COPD) remains a major global health burden, and acute exacerbations (AECOPD) significantly worsen morbidity and mortality. Our study explores the role of prothrombotic biomarkers—fibrinogen, CRP, D-dimer, and vWF—in identifying and differentiating stable and exacerbation phases of COPD.
We found that AECOPD is associated with a distinct hypercoagulable state, emphasizing the growing evidence that inflammation and thrombosis are tightly linked in disease progression. These findings not only shed light on potential diagnostic and prognostic biomarkers but also open pathways for early risk stratification and targeted therapy.
Grateful to my mentors Prof. Virendra Atam sir, Prof. Shyam chand Chaudhary sir, and Dr. Jay Tewari boss for their invaluable guidance and support throughout this work.
Proud to contribute to the evolving understanding of COPD pathophysiology and its clinical management.”
Title: Evaluation of Prothrombotic Biomarkers in Stable and Exacerbation Phases of Chronic Obstructive Pulmonary Disease: A Case-Control Study
Authors: Kamlesh K. Gupta, Shantanu Singh, Virendra Atam, Devansh Mishra, Jay Tewari, Shyam C. Chaudhary, Ajay Patwa
Read full article here
Stay updated with Hemostasis Today.
-
Oct 27, 2025, 12:12Maria Roussakis: It is an Honour to Be a Part of the ISBT Young Professionals Council
-
Oct 27, 2025, 05:47Ahmed Koriesh on The Novel Approach in Use of Tenecteplase
-
Oct 27, 2025, 04:42Louise Breslin: Exciting Results in The CRYPTICS Trial
-
Oct 26, 2025, 16:55ECTH 2025: 3 Unforgettable Days of Science and Shared Purpose
-
Oct 26, 2025, 16:35Ahmed Koriesh on Thrombolysis in Stroke Patients on DOACs
-
Oct 27, 2025, 13:00Hossam El Benawi Shares Multi Site LVT Study from Mayo Clinic
-
Oct 27, 2025, 08:01Acquired Hemophilia A (AHA) is Rare and Often Missed - RPTH Journal
-
Oct 27, 2025, 05:00Wolfgang Miesbach on WFH Guidelines Covering FDA/EMA-Approved AAV Gene Therapy for Hemophilia
-
Oct 26, 2025, 15:04Nita Radhakrishnan and Colleagues on Inherited Haematological Conditions
-
Oct 26, 2025, 14:55Anirban Sen Gupta on Biosynthetic Blood Surrogates Current State-of-Art
-
Oct 25, 2025, 07:42Adithya Hande: India’s Silent Killer and a Scientific Breakthrough
-
Oct 23, 2025, 09:57Arun V. J: Artificial Blood Is Closer Than You Think
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 27, 2025, 13:18Stroke Foundation Welcomes Jacqui McCallum as the New Executive Director
-
Oct 27, 2025, 12:54Guillermo Lahera Forteza on Stroke and Mental Health
-
Oct 27, 2025, 12:37Joshua Ngimbwa Recognised as the Best Male Junior Investigator Awardee at the Tanzania Health Summit
-
Oct 27, 2025, 08:00Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation
-
Oct 27, 2025, 06:30Andres Ricaurte Fajardo on CVT Experience from a Latin American Cohort